Klin Onkol 2005; 18(6): 230-234.
Summary: Colorectal carcinoma is one of the most common malignant diseases in Czech republic. Treatment of stage IV disease is palliative, the main treatment modality is chemotherapy with fluorouracil and leucovorin, irinotecan and oxaliplatin. The over – expression of the epidermal growth factor receptor (EGFR) has been often found in the malignant cells of colorectal cancer. The results of the first series of clinical trials with cetuximab in metastatic colorectal cancer clearly demonstrate a significant activity of this anti-EGFR monoclonal antibody in a setting of patients that are resistant to the currently available active cytotoxic agents. In the following case report we present the significant antitumour activity of irinotecan in combination with cetuximab in patient with metastatic chemoresistent disease.
